lapatinib has been researched along with hydroxychloroquine in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (hydroxychloroquine) | Trials (hydroxychloroquine) | Recent Studies (post-2010) (hydroxychloroquine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 5,885 | 474 | 4,041 |
| Protein | Taxonomy | lapatinib (IC50) | hydroxychloroquine (IC50) |
|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.951 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 4.772 | |
| Toll-like receptor 9 | Homo sapiens (human) | 0.11 | |
| Toll-like receptor 7 | Homo sapiens (human) | 3.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hiramoto, M; Hirota, A; Kazama, H; Miyazaki, M; Miyazawa, K; Ogawa, M; Ota, K; Suzuki, S; Takano, N | 1 |
1 review(s) available for lapatinib and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for lapatinib and hydroxychloroquine
| Article | Year |
|---|---|
Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Fingolimod Hydrochloride; Humans; Hydroxychloroquine; Lapatinib; Lysosomes; Pancreatic Neoplasms; Sphingosine 1 Phosphate Receptor Modulators | 2022 |